Day: November 3, 2024

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future.  In 2025, the separate payments under the Hospital Outpatient Prospective Payment System (OPPS) will be based on Mean Unit Cost (MUC), derived from hospital claims data and apply to any specialized diagnostic radiopharmaceutical...

LEHI, Utah, Nov. 03, 2024 (GLOBE NEWSWIRE) — Complete Solar Holdings, Inc. d/b/a Complete Solar (“Complete Solar” or the “Company”) (Nasdaq: CSLR), a solar technology, services, and installation company, today announced it will release its financial and operational results, for the third quarter of 2024, after market close on Wednesday, November 13, 2024. T.J. Rodgers and the Complete Solar management team will also host a webcast conference call on November 13, 2024, at 5:00 PM ET. Interested parties may access the webcast by registering here, or by visiting the Events page within the Investor Relations section of Complete Solar’s company website at: https://investors.completesolar.com/news-events/events. Please log into the webcast at least 10 minutes prior to the start of the event. A replay of the webcast will be available...

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes. The ordinary shares issuable upon exercise of the warrants are registered...